BioWorld - Sunday, February 1, 2026

Articles by Amanda Lanier

Falling digital graph
Index insights

Alnylam, Incyte and GSK led biopharma gains amid earnings volatility

June 6, 2025
By Amanda Lanier
No Comments
The BioWorld Biopharmaceutical Index extended its downward trend over April and May, closing the latter month down 6.47% after reaching a peak gain of 9.64% at the end of February. The Nasdaq Biotechnology Index followed a similar trajectory, finishing May with a 5.37% decline. Meanwhile, the Dow Jones Industrial Average dipped through April but rebounded slightly in May, ending the month down 0.64%.
Read More
Chikungunya-virus
Index insights

Chikungunya wins boost Valneva; overall infectious disease stocks fall

May 22, 2025
By Amanda Lanier
No Comments
Infectious disease stocks stumbled in the early months of 2025, with the BioWorld Infectious Disease Index (BIDI) plunging 17.83% by the end of April, well behind the broader markets. By comparison, the Nasdaq Biotechnology Index slipped just 1.16%, and the Dow Jones Industrial Average declined 4.41%. In 2024, the BIDI ended the year down 6.28%, after hitting a low of -25.12% in late April.
Read More
Biopharma regulatory actions and approvals April 2025

Atzumi and Vanrafia among 3 NMEs approved by US FDA in April

May 20, 2025
By Amanda Lanier
No Comments
The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This brings the total number of FDA approvals for the first four months of 2025 to 70, a decrease from 77 in the same period last year but higher than the 50 drugs approved during the first four months of 2023 and 48 in 2022. Despite the decrease from last year, the 2025 total remains the second-highest in BioWorld’s records for this time frame.
Read More
Abstract molecules illustration
Biopharma regulatory actions and approvals April 2025

Atzumi and Vanrafia among 3 NMEs approved by US FDA in April

May 19, 2025
By Amanda Lanier
No Comments
The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This brings the total number of FDA approvals for the first four months of 2025 to 70, a decrease from 77 in the same period last year but higher than the 50 drugs approved during the first four months of 2023 and 48 in 2022. Despite the decrease from last year, the 2025 total remains the second-highest in BioWorld’s records for this time frame.
Read More
Stock chart, red down arrow
Index insights

Drug developer stocks fall as companies navigate clinical roadblocks

May 16, 2025
By Amanda Lanier
No Comments
The BioWorld Drug Developers Index underperformed both the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA) throughout February and March. However, it showed some recovery by the end of April, finishing the month down 4.67%, slightly worse than the DJIA’s 4.41% decline. The NBI ended April slightly up from both, with a year-to-date drop of 1.16%.
Read More